Cargando…

Association between body roundness index and non‐alcoholic fatty liver disease detected by Fibroscan in America

BACKGROUND: The prevalence of non‐alcoholic fatty liver disease (NAFLD) and obesity is worldwide on the rise. Body roundness index (BRI), as a newly developed anthropometric indicator, has been recently reported to identify obesity. However, it is still unclear whether BRI is associated with the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Ningning, Zhang, Shengguo, Chu, Jinguo, Yang, Naibin, Lu, Mingqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681427/ https://www.ncbi.nlm.nih.gov/pubmed/37850486 http://dx.doi.org/10.1002/jcla.24973

Ejemplares similares

The association between non‐alcoholic fatty liver disease and serum ferritin levels in American adults
por: Yang, Naibin, et al.
Publicado: (2022)

Diagnostic Performance of Ultrasonography in Detecting Fatty Liver Disease in Comparison with Fibroscan in People Suspected of Fatty Liver
por: Kamali, Leila, et al.
Publicado: (2019)

Effects of lifestyle modification on liver enzyme and Fibroscan in Indian patients with non-alcoholic fatty liver disease
por: Paul, Jayanta, et al.
Publicado: (2018)

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
por: Tuong, Tran Thi Khanh, et al.
Publicado: (2020)

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
por: He, Tingshan, et al.
Publicado: (2020)

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
por: Braude, Michael, et al.
Publicado: (2022)

Deregulation of Regulatory T Cells in Acute-on-Chronic Liver Failure: A Rat Model
por: Ni, Shunlan, et al.
Publicado: (2017)

Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis
por: Al Danaf, Layal, et al.
Publicado: (2022)

Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease
por: Shrestha, Rupesh, et al.
Publicado: (2021)

Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy
por: Malekzadeh, Reza, et al.
Publicado: (2011)

Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease
por: Srivastava, Ankur, et al.
Publicado: (2019)

Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
por: Yang, Andrew, et al.
Publicado: (2021)

Serum uric acid to creatinine ratio is associated with higher prevalence of NAFLD detected by FibroScan in the United States
por: Wang, Rusha, et al.
Publicado: (2022)

The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States
por: Wijarnpreecha, Karn, et al.
Publicado: (2022)

The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
por: Yilmaz, Yusuf, et al.
Publicado: (2023)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Diagnostic Accuracy of FIB-4 and FIB-5 Scores as Compared to Fibroscan for Assessment of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease
por: Kumari, Bandana, et al.
Publicado: (2021)

Body Roundness Index and Waist-to-Height Ratio are Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based Study
por: Motamed, Nima, et al.
Publicado: (2016)

Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis
por: Hashemi, Seyed-Abbas, et al.
Publicado: (2016)

The Efficacy of Anthropometric Indicators in Predicting Non-Alcoholic Fatty Liver Disease Using FibroScan(®) CAP Values among the Taiwanese Population
por: Lee, Meng-Szu, et al.
Publicado: (2023)

Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
por: Bertot, Luis C., et al.
Publicado: (2023)

Update of liver fibrosis and steatosis with transient elastography (Fibroscan)
por: Wong, Grace Lai-Hung
Publicado: (2013)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
por: Yang, Xinyu, et al.
Publicado: (2021)

Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan)
por: Hussain, Azhar, et al.
Publicado: (2019)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
por: Chaidez, Alexander, et al.
Publicado: (2022)

Quantitative Evaluation of Liver Fibrosis on T1 Relaxometry in Comparison with Fibroscan
Publicado: (2020)

Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity
por: Bouferraa, Youssef, et al.
Publicado: (2022)

Combination of Fibrosis-4, liver-stiffness measurement, and Fibroscan-AST score to predict liver-related outcomes in nonalcoholic fatty liver disease
por: Wong, Yu Jun, et al.
Publicado: (2023)

Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities
por: Miura, Kouichi, et al.
Publicado: (2022)

Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
por: Eris, Tansu, et al.
Publicado: (2023)

Diagnostic Performance of Greyscale Ultrasound in Detecting Fatty Liver Disease in a Type 2 Diabetes Population Using FibroScan as the Reference Standard
por: Wiafe, Yaw A, et al.
Publicado: (2023)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease
por: Fallatah, Hind I., et al.
Publicado: (2016)

Laboratory Tests, Liver Vessels Color Doppler Sonography, and FibroScan Findings in Patients with Nonalcoholic Fatty Liver Disease: An Observation Study
por: Alizadeh, Ahmad, et al.
Publicado: (2018)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Amernia, Behnaz, et al.
Publicado: (2021)

Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B
por: HUANG, RENGANG, et al.
Publicado: (2016)

Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment
por: Maklad, Sahar, et al.
Publicado: (2014)

Fibroscan® probe selection for lean adults
por: Stadlbauer, Vanessa, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease may develop in individuals with normal body mass index
por: Margariti, Ekaterini, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vsvm2vnd7sgp4ouvn3qnhf9euv